Published in Cancer Weekly, March 15th, 1999
The allowed claims cover not only the use of recombinant PSA, but also the use of viral constructs containing cDNA encoding PSA and the use of naked DNA for vaccine therapy. PSA is a key antigen currently under clinical investigation by a number of biotechnology and pharmaceutical companies in vaccines for therapy of prostate cancer.
"PSA is an ideal antigen for use in the development of vaccines for therapy of prostate cancer," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.